Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.39 -0.03 (-2.11%)
Market Cap 1.46M
Revenue (ttm) 0.00
Net Income (ttm) -8.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 16,700
Avg Vol 202,904
Day's Range N/A - N/A
Shares Out 1.03M
Stochastic %K 15%
Beta 1.24
Analysts Strong Buy
Price Target $10.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
extracash7751
extracash7751 Aug. 19 at 12:54 PM
$SXTC bio-stocks running $VRAX $BDRX $BDRX its time for $SXTC low float, Est. NET cash/Sh: 31.19
0 · Reply
TA_Kongen
TA_Kongen Aug. 19 at 12:47 PM
$BDRX There is a chance we see a pump somewhere soon here. F-1 in effect. Exit liquidity + positioning for offering.
0 · Reply
premarketmaker
premarketmaker Aug. 19 at 12:37 PM
$BDRX have you ever? if you are thinking about entering - review this - - - unbelievable
0 · Reply
RTPRwire
RTPRwire Aug. 19 at 12:33 PM
$BDRX is trading sharply higher on clinical trial results following a Globe Newswire release. Biodexa announces 87 of 168 subjects (52%) recruited for Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. RTPR pushed this release out to users at 8:30:00 AM ET
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 19 at 12:31 PM
$BDRX Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
0 · Reply
ShangVXO
ShangVXO Aug. 19 at 11:41 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $NVVE & $BDRX on much better footing
0 · Reply
okjasa
okjasa Aug. 19 at 10:49 AM
$BDRX
0 · Reply
flufever
flufever Aug. 19 at 7:38 AM
$BDRX game over again
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 8:41 PM
$SQFT $BDRX $BATL $AIMD $JBDI pick
2 · Reply
luckyluke17
luckyluke17 Aug. 10 at 10:33 PM
$BDRX SI report comes out tomorrow after hours, first since restructuring. Hopefully a PR with the pressure and we are off
0 · Reply
Latest News on BDRX
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Aug 19, 2026, 8:30 AM EDT - 53 minutes ago

Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP

Biodexa Pharmaceuticals Registration statement: Registration filing

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Biodexa Pharmaceuticals Registration statement: Registration filing

Result of General Meeting

Jul 29, 2026, 4:30 PM EDT - 20 days ago

Result of General Meeting

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

Jul 29, 2026, 8:30 AM EDT - 21 days ago

Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France

Biodexa Pharmaceuticals Registration statement: Registration filing

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Biodexa Pharmaceuticals Registration statement: Registration filing

Result of Annual General Meeting

Jun 30, 2026, 4:30 PM EDT - 7 weeks ago

Result of Annual General Meeting

Biodexa Pharmaceuticals announces pricing of $3.5M registered offering

2026-06-30T12:21:15.000Z - 7 weeks ago

Biodexa Pharmaceuticals announces pricing of $3.5M registered offering

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Jun 30, 2026, 8:00 AM EDT - 7 weeks ago

Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants

Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial

2026-06-29T13:15:56.000Z - 7 weeks ago

Biodexa Pharmaceuticals receives Health Canada approval for Serenta trial

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Jun 29, 2026, 8:30 AM EDT - 7 weeks ago

Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress

Postponement and Re-scheduling of Annual General Meeting

Jun 17, 2026, 4:30 PM EDT - 2 months ago

Postponement and Re-scheduling of Annual General Meeting

Biodexa issues letter to Shareholders

May 14, 2026, 8:30 AM EDT - 3 months ago

Biodexa issues letter to Shareholders

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

2026-04-02T23:50:17.000Z - 4 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, news pending

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

2026-04-02T13:12:12.000Z - 4 months ago

Biodexa Pharmaceuticals announces MTX240 manufacturing pact with Syngene

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Apr 2, 2026, 8:30 AM EDT - 4 months ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Biodexa, Tanner Pharma launch global early access program for FAP patients

2026-03-31T12:47:27.000Z - 5 months ago

Biodexa, Tanner Pharma launch global early access program for FAP patients

Preliminary Results for the Year Ended 31 December 2025

Mar 27, 2026, 5:00 PM EDT - 5 months ago

Preliminary Results for the Year Ended 31 December 2025

Biodexa Pharmaceuticals management to meet with Maxim

2026-03-23T14:45:08.000Z - 5 months ago

Biodexa Pharmaceuticals management to meet with Maxim

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Mar 23, 2026, 8:30 AM EDT - 5 months ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

2026-03-18T21:10:28.000Z - 5 months ago

Biodexa Pharmaceuticals announces one-for-five reverse ADR split

ADR Ratio Change

Mar 18, 2026, 5:00 PM EDT - 5 months ago

ADR Ratio Change

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

2026-03-09T12:40:09.000Z - 5 months ago

Biodexa Pharmaceuticals supports Life’s a Polyp Foundation

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Mar 9, 2026, 8:30 AM EDT - 5 months ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 19, 2026, 7:30 AM EST - 6 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

2026-02-04T13:36:46.000Z - 6 months ago

Biodexa Pharmaceuticals announces exclusive license with Otsuka Pharmaceutical

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Feb 4, 2026, 8:30 AM EST - 6 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

2026-01-05T13:41:08.000Z - 8 months ago

Biodexa Pharmaceuticals promotes Fiona Sharp to CFO, secretary

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 8 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

2025-12-18T13:35:26.000Z - 8 months ago

Biodexa Pharmaceuticals prices 157,000 units at $3.28 in public offering

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 8 months ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Pharmaceuticals PLC-ADR trading resumes

2025-12-08T14:41:04.000Z - 9 months ago

Biodexa Pharmaceuticals PLC-ADR trading resumes

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

2025-12-08T14:35:30.000Z - 9 months ago

Biodexa Pharmaceuticals PLC-ADR trading halted, volatility trading pause

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

2025-12-01T13:35:58.000Z - 9 months ago

Biodexa announces enrollment of first European patients in Phase 3 Serenta trial

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 9 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

2025-11-24T13:45:58.000Z - 9 months ago

Biodexa Pharmaceuticals activates first European Site for Phase 3 Serenta trial

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 9 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Pharmaceuticals files to sell 3.38M units

2025-11-17T22:05:23.000Z - 9 months ago

Biodexa Pharmaceuticals files to sell 3.38M units

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

2025-11-03T13:35:20.000Z - 10 months ago

Biodexa announces approval of CTA by EMA of Phase 3 trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 10 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 11 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Biodexa Pharmaceuticals files $100M mixed securities shelf

2025-09-26T21:05:13.000Z - 11 months ago

Biodexa Pharmaceuticals files $100M mixed securities shelf

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 1 year ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 1 year ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 1 year ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 1 year ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 1 year ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

extracash7751
extracash7751 Aug. 19 at 12:54 PM
$SXTC bio-stocks running $VRAX $BDRX $BDRX its time for $SXTC low float, Est. NET cash/Sh: 31.19
0 · Reply
TA_Kongen
TA_Kongen Aug. 19 at 12:47 PM
$BDRX There is a chance we see a pump somewhere soon here. F-1 in effect. Exit liquidity + positioning for offering.
0 · Reply
premarketmaker
premarketmaker Aug. 19 at 12:37 PM
$BDRX have you ever? if you are thinking about entering - review this - - - unbelievable
0 · Reply
RTPRwire
RTPRwire Aug. 19 at 12:33 PM
$BDRX is trading sharply higher on clinical trial results following a Globe Newswire release. Biodexa announces 87 of 168 subjects (52%) recruited for Phase 3 Serenta trial of eRapa in familial adenomatous polyposis. RTPR pushed this release out to users at 8:30:00 AM ET
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 19 at 12:31 PM
$BDRX Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
0 · Reply
ShangVXO
ShangVXO Aug. 19 at 11:41 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $NVVE & $BDRX on much better footing
0 · Reply
okjasa
okjasa Aug. 19 at 10:49 AM
$BDRX
0 · Reply
flufever
flufever Aug. 19 at 7:38 AM
$BDRX game over again
0 · Reply
JimmyOcarri
JimmyOcarri Aug. 17 at 8:41 PM
$SQFT $BDRX $BATL $AIMD $JBDI pick
2 · Reply
luckyluke17
luckyluke17 Aug. 10 at 10:33 PM
$BDRX SI report comes out tomorrow after hours, first since restructuring. Hopefully a PR with the pressure and we are off
0 · Reply
The_Gambl3r
The_Gambl3r Aug. 7 at 5:50 PM
$BDRX $CNSY
1 · Reply
The_Gambl3r
The_Gambl3r Aug. 7 at 4:59 PM
$NUWE Really liking that round 1.50. Imma Russian doll these Mofos. $BDRX $CNSY
1 · Reply
Schizoo
Schizoo Aug. 6 at 3:53 PM
$BDRX hold this one😘
0 · Reply
luckyluke17
luckyluke17 Aug. 6 at 12:05 PM
$BDRX at this cost to borrow, if you shorted 10K on April 7th, even with the drop you'd be lucky to be green, probably down a couple grand. Small wins
0 · Reply
Schizoo
Schizoo Aug. 5 at 8:44 PM
$BDRX this one is a no brainer.. low float. More buyers tha sellers.. shorts gonna give us a run..🤷‍♂️
0 · Reply
luckyluke17
luckyluke17 Aug. 5 at 8:24 PM
$BDRX more borrowed than returned today and up 8%, small wins. Also pay no attention to the SI numbers was multiple hundreds of % for months and nothing 😂
0 · Reply
The_Gambl3r
The_Gambl3r Aug. 5 at 7:32 PM
$BDRX $NUWE 🤨👀
1 · Reply
The_Gambl3r
The_Gambl3r Aug. 5 at 3:19 PM
$NUWE $BDRX
0 · Reply
Schizoo
Schizoo Aug. 5 at 9:15 AM
$BDRX BALLS N PATIENCE PEOPLE
0 · Reply
The_Gambl3r
The_Gambl3r Aug. 5 at 3:37 AM
$BDRX So AH range 2.15-1.31 (.84) on 8/4? Hmm lol.
0 · Reply
The_Gambl3r
The_Gambl3r Aug. 4 at 9:27 PM
$BDRX She’s feisky
0 · Reply
Schizoo
Schizoo Aug. 4 at 9:22 PM
$BDRX 🤷‍♂️🤌😘
0 · Reply